Newsadmin2020-07-22T00:29:58-04:00

News

Source: NASDAQ

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Published on 2020-09-10
EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
Published on 2020-08-24
EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
Published on 2020-08-20
EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Published on 2020-08-05
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®
Published on 2020-08-04
EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information
Published on 2020-07-29
EyePoint Pharmaceuticals Presents Data Supporting YUTIQ® at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting
Published on 2020-07-27
EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer
Published on 2020-07-13
EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Published on 2020-05-26
EyePoint Pharmaceuticals Presents Data Showcasing DEXYCU® at the American Society of Cataract and Refractive Surgery 2020 Virtual Annual Meeting
Published on 2020-05-18
EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Published on 2020-05-06
EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information
Published on 2020-04-29
EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update
Published on 2020-04-01
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress
Published on 2020-03-05
EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®
Published on 2020-03-02
EyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information
Published on 2020-02-27
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Published on 2020-02-21
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Published on 2020-02-20
EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU®
Published on 2020-02-18
EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion
Published on 2020-02-03